Related references
Note: Only part of the references are listed.Proteinuria selectivity index predicts response to rituximab in adults with minimal change disease and focal segmental glomerulosclerosis
Marco Allinovi et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2022)
Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?
Venkat R. Reddy et al.
RHEUMATOLOGY (2022)
The evolution of the therapeutic approach to membranous nephropathy
Claudio Ponticelli et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)
The ISCCA flow protocol for the monitoring of anti-CD20 therapies in autoimmune disorders
Arianna Gatti et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2021)
Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy
Roberta Fenoglio et al.
JOURNAL OF NEPHROLOGY (2021)
Retrospective single-arm cohort study of steroid-dependent minimal change nephrotic syndrome treated with very low-dose rituximab
Keiji Fujimoto et al.
CLINICAL NEPHROLOGY (2021)
Rituximab for the management of idiopathic membranous nephropathy: a meta-analysis
Lan Huang et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2021)
Successful treatment of PLA2R1-antibody positive membranous nephropathy with ocrelizumab
Tilman Schmidt et al.
JOURNAL OF NEPHROLOGY (2021)
Membranous nephropathy: current understanding of various causes in light of new target antigens
Pierre Ronco et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2021)
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
Brad H. Rovin et al.
KIDNEY INTERNATIONAL (2021)
Rituximab in primary membranous nephropathy: a comparative study of three dosing regimens
Raja Ramachandran et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy
Gema Fernandez-Juarez et al.
KIDNEY INTERNATIONAL (2021)
Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia
Etienne Crickx et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Single-Cell Transcriptomic Analyses Define Distinct Peripheral B Cell Subsets and Discrete Development Pathways
Alexander Stewart et al.
FRONTIERS IN IMMUNOLOGY (2021)
Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial
Pietro Ravani et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)
Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes
Eugene Yu-Hin Chan et al.
KIDNEY INTERNATIONAL (2020)
Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children
Koichi Kamei et al.
PEDIATRIC NEPHROLOGY (2020)
Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab
Lionel Rouge et al.
SCIENCE (2020)
Successful Treatment of Patients With Refractory PLA2R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases
Nattawat Klomjit et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis
Panupong Hansrivijit et al.
BMC NEPHROLOGY (2020)
Rituximab in maintaining remission in adults with podocytopathy
Raja Ramachandran et al.
NEPHROLOGY (2020)
Personalized Medicine for PLA2R1-Related Membranous Nephropathy: A Multicenter Randomized Control Trial
Vesna Brglez et al.
FRONTIERS IN MEDICINE (2020)
B cells reappear less mature and more activated after their anti-CD20-mediated depletion in multiple sclerosis
Nitzan Nissimov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Multi-Autoantibody Signature and Clinical Outcome in Membranous Nephropathy
Gian Marco Ghiggeri et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Autoimmunity in Focal Segmental Glomerulosclerosis: A Long-Standing Yet Elusive Association
Manuel Alfredo Podesta et al.
FRONTIERS IN MEDICINE (2020)
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
Philipp Gauckler et al.
AUTOIMMUNITY REVIEWS (2020)
Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients with Severe Membranous Nephropathy: Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab
Manuel Alfredo Podesta et al.
NEPHRON (2020)
Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study
Takayuki Katsuno et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2019)
Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study
Toshiyuki Takahashi et al.
PEDIATRIC NEPHROLOGY (2019)
Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome
Julien Hogan et al.
PEDIATRIC NEPHROLOGY (2019)
Rituximab bioavailability in primary membranous nephropathy
Sonia Boyer-Suavet et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2019)
High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy
Barbara Seitz-Polski et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy
F. C. Fervenza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Rituximab Exhibits Altered Pharmacokinetics in Patients With Membranous Nephropathy
Uma Fogueri et al.
ANNALS OF PHARMACOTHERAPY (2019)
Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders
Gisa Ellrichmann et al.
JOURNAL OF NEUROLOGY (2019)
Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody
K. Dahan et al.
KIDNEY INTERNATIONAL (2019)
Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy
Raja Ramachandran et al.
NEPHROLOGY (2019)
Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome
Andrew P. Maxted et al.
PEDIATRIC NEPHROLOGY (2019)
Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome
Frank B. Cortazar et al.
CLINICAL KIDNEY JOURNAL (2019)
Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy
Barbara Seitz-Polski et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort
Xin Wang et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution
Keith A. Sacco et al.
IMMUNOTHERAPY (2018)
Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach
An S. De Vriese et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab
Anne-Els van de Logt et al.
KIDNEY INTERNATIONAL (2018)
Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome
Roberta Fenoglio et al.
Oncotarget (2018)
Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome A Randomized Clinical Trial
Biswanath Basu et al.
JAMA PEDIATRICS (2018)
Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome A multicenter open-label trial in Korea
Yo Han Ahn et al.
MEDICINE (2018)
Rituximab and Fibrillary Glomerulonephritis: Interest of B Cell Reconstitution Monitoring
Claire Leibler et al.
JOURNAL OF CLINICAL MEDICINE (2018)
Ocrelizumab: a new milestone in multiple sclerosis therapy
Patricia Mulero et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2018)
Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion
Mai Sato et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2018)
Rituximab for nephrotic syndrome in children
Kazumoto Iijima et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2017)
Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up
Karine Dahan et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Kinetic analysis of changes in T- and B-lymphocytes after anti-CD20 treatment in renal pathology
Alexis Sentis et al.
IMMUNOBIOLOGY (2017)
Detection and quantification of rituximab in the human urine
Roland Jacobs et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2017)
B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab
Michelle Rosenzwajg et al.
KIDNEY INTERNATIONAL (2017)
Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years
Franck Pourcine et al.
PLOS ONE (2017)
Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples
Venkat Reddy et al.
RHEUMATOLOGY (2017)
Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis
Hong Ren et al.
ONCOTARGET (2017)
High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study
Dario Roccatello et al.
AMERICAN JOURNAL OF NEPHROLOGY (2017)
Obinutuzumab: what is there to learn from clinical trials?
Guillaume Cartron et al.
BLOOD (2017)
B Cells, Antibodies, and More
William Hoffman et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome
Manuela Colucci et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
B cell depletion with rituximab in patients with rheumatoid arthritis: Multiplex bead array reveals the kinetics of IgG and IgA antibodies to citrullinated antigens
Geraldine Cambridge et al.
JOURNAL OF AUTOIMMUNITY (2016)
Circulating (CD3-CD19+CD20-IgD-CD27highCD38high) Plasmablasts: A Promising Cellular Biomarker for Immune Activity for Anti-PLA2R1 Related Membranous Nephropathy?
Agnieszka Pozdzik et al.
MEDIATORS OF INFLAMMATION (2016)
Minimal change disease and idiopathic FSGS: manifestations of the same disease
Rutger J. Maas et al.
NATURE REVIEWS NEPHROLOGY (2016)
Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting
Wolfgang Merkt et al.
ARTHRITIS RESEARCH & THERAPY (2016)
Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study
A. -P. Trouvin et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2015)
Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy
Piero Ruggenenti et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial
Pietro Ravani et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome
Clare E. Counsilman et al.
PEDIATRIC NEPHROLOGY (2015)
Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome
Aditi Sinha et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2015)
Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease
Nils Venhoff et al.
AUTOIMMUNITY (2014)
Rituximab Treatment Prevents the Early Development of Proteinuria following Pig-to-Baboon Xeno-Kidney Transplantation
Masayuki Tasaki et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome
Piero Ruggenenti et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Phospholipase A2 Receptor Autoantibodies and Clinical Outcome in Patients with Primary Membranous Nephropathy
Elion Hoxha et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial
Kazumoto Iijima et al.
LANCET (2014)
Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy
Nicola M. Tomas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ofatumumab for Rituximab- Resistant Nephrotic Syndrome
Biswanath Basu
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Rituximab in immunologic glomerular diseases
A. Ahsan Ejaz et al.
MABS (2012)
Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood-follow-up after CD19 recovery
Anne-Laure Sellier-Leclerc et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome
Markus J. Kemper et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Short-Term Effects of Rituximab in Children with Steroid- and Calcineurin-Dependent Nephrotic Syndrome: A Randomized Controlled Trial
Pietro Ravani et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Anti-Phospholipase A2 Receptor Antibodies Correlate with Clinical Status in Idiopathic Membranous Nephropathy
Julia M. Hofstra et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Long-lived autoreactive plasma cells drive persistent autoimmune inflammation
Falk Hiepe et al.
NATURE REVIEWS RHEUMATOLOGY (2011)
Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis
Alessia Fornoni et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study
Fernando C. Fervenza et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Rituximab in refractory nephrotic syndrome
Agnieszka Prytula et al.
PEDIATRIC NEPHROLOGY (2010)
Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine
Shuichiro Fujinaga et al.
PEDIATRIC NEPHROLOGY (2010)
CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies
Stephen A. Beers et al.
SEMINARS IN HEMATOLOGY (2010)
Rituximab Treatment of Adult Patients with Steroid-Resistant Focal Segmental Glomerulosclerosis
Gema Fernandez-Fresnedo et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Cytokine-Producing Effector B Cells Regulate Type 2 Immunity to H. polygyrus
Wojciech Wojciechowski et al.
IMMUNITY (2009)
M-Type Phospholipase A(sub 2) Receptor as Target Antigen in Idiopathic Membranous Nephropathy.
Laurence H. Beck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children
Koichi Kamei et al.
PEDIATRIC NEPHROLOGY (2009)
Highly Sensitive B Cell Analysis Predicts Response to Rituximab Therapy in Rheumatoid Arthritis
Shouvik Dass et al.
ARTHRITIS AND RHEUMATISM (2008)
Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy
Paolo Cravedi et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome?
Graham C. Smith
PEDIATRIC NEPHROLOGY (2007)
Rituximab for idiopathic membranous nephropathy: Who can benefit?
Piero Ruggenenti et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Complement activation plays a key role in the side-effects of rituximab treatment
LE van der Kolk et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Share Paper
